Abstract
The guinea pig is a very useful animal model for evaluating new tuberculosis candidate vaccines. In addition to established methods for bacterial load determinations, new technologies are emerging that allow us to specifically evaluate effects of vaccines on the pathology of the disease process and the expression by the host of cell mediated immunity. Limitations to the model include housing and related costs, which often contribute to issue with study design and adequate statistical power, and the use of laboratory strains of Mycobacterium tuberculosis which lack the high virulence and immune evasion properties of newly emerging clinical isolates.
| Original language | English |
|---|---|
| Pages (from-to) | 389-397 |
| Number of pages | 9 |
| Journal | Tuberculosis |
| Volume | 89 |
| Issue number | 6 |
| DOIs |
|
| Publication status | Published - Nov 2009 |
Bibliographical note
Funding Information:This work was supported by European Union grants 5 (QKL2-CT1999-01093) and 6 (LSHP-CT-2004-503367 and LSHP-CT-2003-503240), and by the Department of Health, UK, and by NIH Grant AI070456.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Guinea pigs
- Statistical limitation
- Vaccination
Fingerprint
Dive into the research topics of 'Evaluation of new vaccines for tuberculosis in the guinea pig model'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver